Growth Equity Opportunities V, LLC
revealed that they own 6% of CTI BioPharma Corp (NASDAQ:CTIC) in a Form 13D disclosure that was filed with the Securities and Exchange Commission (SEC) on Tuesday, February 20th. The investor owns 3,750,000 shares of the stock valued at about $14,100,000. The reporting parties listed on the disclosure included Growth Equity Opportunities Fund V, LLC, New Enterprise Associates 16, LP, NEA Partners 16, LP, Nea 16 Gp, LLC, Peter J Barris, Forest Baskett, Anthony A Florence, Jr, Mohamad H Makhzoumi, Joshua Makower, David M Mott, Chetan Puttagunta, Jon M Sakoda, Scott D Sandell, Peter W Sonsini and Ravi Viswanathan. The disclosure is available through Edgar at this hyperlink.
In other news, major shareholder Bvf Partners L. P/Il purchased 5,634,108 shares of the stock in a transaction dated Friday, February 9th. The stock was acquired at an average cost of $3.00 per share, for a total transaction of $16,902,324.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Value Fund L. P. Biotechnology purchased 6,333,333 shares of the stock in a transaction dated Friday, February 9th. The shares were purchased at an average price of $3.00 per share, with a total value of $18,999,999.00. The disclosure for this purchase can be found here. Company insiders own 2.16% of the company’s stock.
Separately, Zacks Investment Research lowered CTI BioPharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd.
CTI BioPharma Corp (CTIC) traded up $0.03 on Tuesday, hitting $3.76. The stock had a trading volume of 423,518 shares, compared to its average volume of 486,046. CTI BioPharma Corp has a 1-year low of $2.45 and a 1-year high of $4.79. The stock has a market capitalization of $161.57, a price-to-earnings ratio of -3.65 and a beta of 0.50. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.19.
CTI BioPharma Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Want to see what other hedge funds are holding CTIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CTI BioPharma Corp (NASDAQ:CTIC).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.